2020 Annual Meeting | C207 - Assessment of Rapidly Progressive Dementias 2: Infections and Autoimmune Mediated Conditions

Date Wednesday 04/29/20

Time 03:30 PM - 05:30 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Michael D. Geschwind, MD, PhD, F�鶹��ýӳ��

Topic(s) Aging, Dementia, and Behavioral Neurology

Learning Objectives Participants should be familiar with the differential diagnosis of prion and antibody-mediated causes of RPD and the clinical presentation and evaluation of the more common conditions.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Program Level Intermediate

Program Tracks Advanced Practice Provider

Recommended Audience General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider

Teaching Styles Case-based, Interactive, Audience Participation

Event Timeline
03:30 PM - 03:35 PM	Introduction	Introduction Michael D. Geschwind, MD, PhD, F�鶹��ýӳ��
03:35 PM - 04:25 PM	Speaker	Infections as Rapidly Progressive Dementia Allen J. Aksamit, Jr., MD, F�鶹��ýӳ��
04:25 PM - 05:15 PM	Speaker	Autoimmune Causes of Rapidly Progressive Dementia Jeffrey M. Gelfand, MD, MS, F�鶹��ýӳ��
05:15 PM - 05:30 PM	Q&A	Questions and Answers
05:30 PM - 06:00 PM	Discussion	Continuing the Conversation

Faculty Disclosures
Michael D. Geschwind, MD, PhD, F�鶹��ýӳ��	Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Brainstorm Cell Therapeutics, Inc.. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Walter Grubb. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gerson Lehrman Group. Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Reata Pharmaceuticals, Inc..
Allen J. Aksamit, Jr., MD, F�鶹��ýӳ��	Dr. Aksamit has nothing to disclose.
Jeffrey M. Gelfand, MD, MS, F�鶹��ýӳ��	Dr. Gelfand has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Arialys. Dr. Gelfand has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ventyx Bio. An immediate family member of Dr. Gelfand has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Headache: The Journal of Head and Face Pain. The institution of Dr. Gelfand has received research support from Genentech/Roche. The institution of Dr. Gelfand has received research support from Vigil Neurosciences. An immediate family member of Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has a non-compensated relationship as a Trial Steering Committee Chairperson and member with Roche / Genentech that is relevant to �鶹��ýӳ�� interests or activities.